Antibody-drug conjugates (ADCs) represent a cutting-edge class of targeted cancer ther- apeutics, seamlessly integrating the high specificity of monoclonal antibodies with the cytotoxic power of chemotherapy agents. This strategic union facilitates the precise de- livery of a potent cytotoxic payload to HER2-expressing cancer cells, where HER2 is a well-established therapeutic target. Despite the promising efficacy of HER2-directed ADCs in treating HER2-positive breast cancer, the emergence of resistance in tumor cells poses a significant obstacle to their therapeutic potential.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
